替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2、中期因子水平的影响研究

摘要/Abstract

摘要：

目的: 探究替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2（HER-2）、中期因子（MK）水平的影响。方法: 抽取2010年1月至2016年5月本院收治的64例乳腺癌患者，通过随机数表法分组，各32例。对照组采用三维适形放疗，研究组联合采用三维适形放疗+替吉奥胶囊，共治疗2个疗程。统计对比两组临床疗效、不良反应发生率，分析治疗前后两组肿瘤标志物［癌胚抗原（CEA）、CA125、CA153］及MK、HER-2水平变化情况。结果: 研究组治疗有效率（50.00%）、肿瘤控制率（81.25%）高于对照组（25.00%、53.13%），差异有统计学意义（P<0.05）；治疗前两组CEA、CA125、CA153水平对比差异无统计学意义（P>0.05），经治疗，两组各指标水平较治疗前降低，且研究组CEA、CA125、CA153水平均低于对照组，差异有统计学意义（P<0.05）；治疗前两组HER-2及MK水平对比差异无统计学意义（P>0.05），经治疗，两组各指标水平较治疗前降低，且研究组HER-2及MK水平均低于对照组，差异有统计学意义（P<0.05）；两组均未出现IV度不良反应，研究组白细胞减少、腹泻、呕吐恶心发生率（34.38%、34.38%、37.51%）与对照组（31.24%、37.51%、34.37%）对比，差异无统计学意义（P>0.05）。结论: 替吉奥胶囊联合放疗治疗乳腺癌效果显著，可改善血清肿瘤标志物、HER-2及MK表达水平，且安全性较高，值得推广。

关键词: 替吉奥胶囊, 放疗, 乳腺癌, 肿瘤标志物, 人类表皮生长因子受体-2

Abstract:

AIM: To explore the effect of gimeracil capsules combined with radiotherapy on breast cancer, and on tumor marker, human epidermal growth factor receptor-2 (HER-2) and level of midkine (MK). METHODS: Sixty-four breast cancer patients were selected by random number table method from January 2010 to May 2016 in our hospital, sixty-two cases in each group. The control group was treated with three-dimensional conformal radiotherapy; the study group was treated with three-dimensional conformal radiotherapy and gimeracil capsule; the therapy continued for 2 courses of treatment. Clinical efficacy and adverse reaction incidence rate were compared between two groups; tumor markers (CEA, CA125, CA153) and changes of MK, HER-2 level were analyzed. RESULTS:The effective rate (50%) and tumor control rate (81.25%) of the study group were higher than those of the control group (25%, 53.13%), the difference were statistically significant (P<0.05); Before treatment, no significant difference of CEA, CA125, CA153 was observed between groups (P>0.05), while all the indexes decreased after treatment, and the study group presented more significant change than the control group (P<0.05); Before treatment, no significant difference of HER-2 and MK level was observed between groups (P>0.05), while all the indexes decreased after treatment, and the study group presented more significant change than the control group (P<0.05). Both groups presented no IV degrees of adverse reactions, and compared with control group (31.24%, 37.51%, 34.37%), the incidence of leucopenia, diarrhea, nausea and vomiting (34.38%, 34.38%, 37.51%) of the study group presented no statistically significance (P>0.05). CONCLUSION: Gimeracil capsules combined with radiotherapy exhibited remarkable effect on breast cancer, and on the serum tumor markers, human epidermal growth factor receptor-2 and midkine expression level. With high safety, it is worthy of promotion.

Key words: gimeracil capsules, radiotherapy, breast cancer, tumor marker, human epidermal growth factor receptor-2

中图分类号:

R965.2

闫建强，聂改红. 替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2、中期因子水平的影响研究[J]. 中国临床药理学与治疗学, 2017, 22(8): 899-903.

YAN Jianqiang,NIE Gaihong. Effect of gimeracil capsules combined with radiotherapy on breast cancer and on tumor markers, human epidermal growth factor receptor-2 and midkine levels[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 899-903.

参考文献

［1］Matzinger O, Heimsoth I, Poortmans P,et al.Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)［J］. Acta Oncol,2010,49(1):24-34.
［2］罗代琴,冉立,常建英,等.辅助放化疗在Ⅰ~Ⅱ期乳腺癌保乳术后的治疗效果［J］.贵阳医学院学报,2015,40(3):288-290.
［3］Kim KH, Noh JM, Kim YB,et al.Does internal mammary node irradiation affect treatment outcome in clinical stage II-III breast cancer patients receiving neoadjuv ant chemotherapy［J］ ? Breast Cancer Res Treat,2015,152(3):589-599.
［4］郑瑛,陈钦,贾苗苗,等.保乳术后放疗对乳腺癌局部淋巴结转移患者预后的影响［J］.中国肿瘤临床,2014,41(21):1394-1398.
［5］张锡贵,李太东,倪武,等.早期乳腺癌保乳手术联合放化疗治疗方案的临床研究［J］.中国现代普通外科进展,2015,18(9):709-711.
［6］陈孝平,汪建平.外科学［M］.8版.北京:人民卫生出版社,2013:256-260.
［7］席娟,郄远巍.新辅助化疗联合乳腺癌改良根治术对乳腺癌组织中分子标志物Survivin、HER-2、p53表达的影响及意义［J］.临床和实验医学杂志,2016,15(12):1183-1186.
［8］李树玲.乳腺肿瘤学［M］.2 版.北京:科学技术文献出版社,2007:978-987．
［9］Chung Y, Kim JW, Shin KH,et al.Dummy run of quality assurance program in a phase 3 randomized trial investigating the role of internal mammary lymph node irradiation in breast cancer patients: Korean Radiation Oncology Group 08-06 study［J］.IInt J Radiat Oncol Biol Phys,2015,91(2):419-426.
［10］张芹,颜淑霞,马杰,等.三维适形放疗联合S-1治疗局部晚期胰腺癌临床观察［J］.现代肿瘤医学,2014,22(1):129-131.
［11］李继恩,王旭东,姜在鹏,等.替吉奥口服联合三维适形放疗治疗三阴性乳腺癌效果观察［J］.山东医药,2016,56(18):45-47.
［12］Yeung R, Conroy L, Long K,et al.Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation［J］. Radiat Oncol, 2015,10(1):200.
［13］Tyran M, Mailleux H, Tallet A,et al.Volumetric-modulated arc therapy for left-sided breast cancer and all regional nodes improves target volumes coverage and reduces treatment time and doses to the heart and left coronary artery, compared with a field-in-field technique［J］. J Radiat Res,2015,56(6):927-937.
［14］郑婷,钱其军.替吉奥治疗晚期乳腺癌的研究进展［J］.药学实践杂志,2015,33(6):557-560.
［15］高彤,王晓燕,赵丽霞,等.食管胃结合部癌治疗中替吉奥胶囊同步三维适形放疗的临床应用［J］.疑难病杂志,2014,13(7):690-693.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[9]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[10]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[11]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[12]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[13]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[14]	徐国防, 张思森, 刘平, 梅家转, 刘玮玮, 刘亚欧, 齐琦. 卡培他滨在中国乳腺癌患者中的群体药代动力学研究[J]. 中国临床药理学与治疗学, 2021, 26(5): 552-559.
[15]	孙红, 侯佳林, 蔡加琴, 魏晓霞, 庄捷. SUMO E3连接酶介导雄激素受体的转录促进乳腺癌他莫昔芬耐药[J]. 中国临床药理学与治疗学, 2021, 26(3): 285-291.